Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) shares saw unusually-high trading volume on Monday . Approximately 1,626,927 shares changed hands during trading, an increase of 302% from the previous session’s volume of 405,070 shares.The stock last traded at $4.05 and had previously closed at $3.50.

The company’s 50-day moving average is $3.50 and its 200 day moving average is $4.38. The stock’s market capitalization is $249.99 million.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last issued its quarterly earnings results on Tuesday, May 10th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.48. The firm had revenue of $8.10 million for the quarter, compared to the consensus estimate of $9.70 million. The firm’s revenue for the quarter was up 84.1% on a year-over-year basis. Analysts anticipate that Aralez Pharmaceuticals Inc. will post ($1.00) EPS for the current year.

In related news, insider Andrew I. Koven purchased 71,500 shares of the firm’s stock in a transaction dated Thursday, May 12th. The stock was bought at an average price of $3.49 per share, for a total transaction of $249,535.00. Following the purchase, the insider now directly owns 1,610,306 shares in the company, valued at approximately $5,619,967.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Arthur S. Kirsch purchased 27,500 shares of the firm’s stock in a transaction dated Thursday, May 12th. The shares were bought at an average price of $3.49 per share, with a total value of $95,975.00. Following the purchase, the director now owns 96,609 shares in the company, valued at $337,165.41. The disclosure for this purchase can be found here.

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.